Highlighting key issues and differences among GMPs of Europe, Canada, and the WHO, this reference examines US law and governmental policy affecting domestic and multinational pharmaceutical manufacturing. The book recommends pragmatic ways to interpret and comply with FDA CGMP regulation and related criteria. The author focuses on: geographical redistribution of manufacturing facilities; accommodation of a diversity of regulatory and statutory governance; adaptation to disparate human resources; new growth areas of manufacture and distribution of homeopathic remedies and dietary supplements; and the greater quality control required of pharmacists and other authorized dispensers.